Climb Bio Analyst Price Targets - Benzinga

Climb Bio Inc

CLYMNASDAQ

Trade with Public

Trade with Public

$15.05

-0.85-5.35%

At close: Sep 9, 5:00 PM EST

$15.30

0.251.66%

After Hours: 6:44 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Climb Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Climb Bio (CLYM).

Price Target Range — 6 Quarters

Analyst Consensus — 14 Analysts

1S.Buy

13Buy

Consensus RatingBuy# Analysts14Avg. Consensus PT$25Upside to Avg. PT+60.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 8, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$18→$25
Sep 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$24→$30
Sep 4, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$26→$30
Sep 3, 2026	BTIG	Julian Harrison	PT Raise	Buy	$20→$32
Sep 3, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$21→$25
Aug 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$20→$24
Aug 19, 2026	Wedbush	Laura Chico	Maintained	Outperform	$20
Aug 7, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$17→$25
Jul 27, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$17→$20
Jun 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Jun 12, 2026	Wedbush	Laura Chico	Maintained	Outperform	$17
Jun 11, 2026	BTIG	Julian Harrison	PT Raise	Buy	$19→$20
Jun 8, 2026	Guggenheim	Yatin Suneja	Initiate	Buy	$35
Jun 8, 2026	BTIG	Julian Harrison	Maintained	Buy	$19
May 12, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$15→$20
May 8, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$15→$17
May 6, 2026	BTIG	Julian Harrison	PT Raise	Buy	$8→$19
May 5, 2026	Chardan Capital	Geulah Livshits	Initiate	Buy	$22
Apr 21, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$10→$18
Apr 15, 2026	Mizuho	Joseph Catanzaro	Initiate	Outperform	$18

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25

Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.

Benzinga Newsdesk

Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30

B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25

Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.

Benzinga Newsdesk